Stryker Corp
SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3020% below fair value
$306.81+14.95 (+5.12%)
Close on Nov 2, 2026Market cap $117.68BP/E 32.7Yield –
Stryker Trauma and Extremities by Quarter
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — U.S. Net Sales ($M) ($M)
Stryker Trauma and Extremities: $735M in Q3 2026, up 4.6% from a year earlier.
Latest, Q3 2026
735
Period ended Sep 30, 2026
Change on a year earlier
+4.6%
703 in Q3 2025
History
21 quarters
Since Q1 2021
Sources
7
Documents cited below
Where the Q3 2026 figure comes from
Reported in Stryker Form 8-K Supplemental Sales Schedules, Recast 8-K & Form 10-K/10-Q Note 15.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — U.S. Net Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 735 | +4.6% | 0000310764-26-000059|sykex991earningsq32026.htm ↗ |
| Q2 2026 | Jun 30, 2026 | 791 | +12.7% | 0000310764-26-000048|sykex991earningsq22026.htm ↗ |
| Q1 2026 | Mar 31, 2026 | 767 | +7.6% | 0000310764-26-000031|syk-20260331.htm ↗ |
| Q4 2025 | Dec 31, 2025 | 808 | +8.6% | ir|change_in_pres_2026Q1 ↗ |
| Q3 2025 | Sep 30, 2025 | 703 | +13.2% | ir|change_in_pres_2026Q1 ↗ |
| Q2 2025 | Jun 30, 2025 | 702 | +15.1% | ir|change_in_pres_2026Q1 ↗ |
| Q1 2025 | Mar 31, 2025 | 713 | +16.7% | ir|change_in_pres_2026Q1 ↗ |
| Q4 2024 | Dec 31, 2024 | 744 | +17.5% | ir|change_in_pres_2026Q1 ↗ |
| Q3 2024 | Sep 30, 2024 | 621 | +12.9% | ir|change_in_pres_2026Q1 ↗ |
| Q2 2024 | Jun 30, 2024 | 610 | +9.1% | ir|change_in_pres_2026Q1 ↗ |
| Q1 2024 | Mar 31, 2024 | 611 | +10.3% | ir|change_in_pres_2026Q1 ↗ |
| Q4 2023 | Dec 31, 2023 | 633 | – | ir|change_in_pres_2026Q1 ↗ |
| Q3 2023 | Sep 30, 2023 | 550 | +11.3% | ir|change_in_pres_2026Q1 ↗ |
| Q2 2023 | Jun 30, 2023 | 559 | +14.3% | ir|change_in_pres_2026Q1 ↗ |
| Q1 2023 | Mar 31, 2023 | 554 | +13.8% | ir|change_in_pres_2026Q1 ↗ |
| Q3 2022 | Sep 30, 2022 | 494 | +10.5% | 0000310764-22-000105|syk-20220930.htm ↗ |
| Q2 2022 | Jun 30, 2022 | 489 | +2.9% | 0000310764-22-000092|syk-20220630.htm ↗ |
| Q1 2022 | Mar 31, 2022 | 487 | +10.7% | 0000310764-22-000062|syk-20220331.htm ↗ |
| Q3 2021 | Sep 30, 2021 | 447 | – | 0000310764-22-000105|syk-20220930.htm ↗ |
| Q2 2021 | Jun 30, 2021 | 475 | – | 0000310764-22-000092|syk-20220630.htm ↗ |
| Q1 2021 | Mar 31, 2021 | 440 | – | 0000310764-22-000062|syk-20220331.htm ↗ |
Breakdown
What makes up trauma and Extremities
Cite this data
StockData. (2026). Stryker Trauma and Extremities ($M), quarterly Q1 2021–Q3 2026 [Data set]. Compiled from Stryker SEC filings and investor materials. https://stockdatahq.com/stocks/syk/kpis/fran-trauma-us-rev
See every metric in the Stryker KPI table. Data updated Nov 2, 2026.